TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01652092
Drug: Fludarabine phosphate 40 mg
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m\^2 IV on days -5 through -2 (for children \< 6 months and/or \< 10 kg weight dose at 1.33 mg/kg)
Study: NCT01652092
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg/m\^2 IV on day -3
Study: NCT01652092
Drug: Alemtuzumab 0.2 mg
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.2 mg/kg intravenously (IV) on days -14 through -10
Study: NCT01652092
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
Study: NCT01652092
Drug: Fludarabine phosphate 30 mg
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fludarabine 30 mg/m\^2 IV on days -8 through -4
Study: NCT01652092
Drug: MESNA
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered as per the standard institutional protocol.
Study: NCT00569920
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
Study: NCT02159482
Drug: Interferon Alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01296568
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT01296568
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT01004003
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04733183
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
Study: NCT04733183
Drug: onfekafusp alfa
Normalized name: Onfekafusp alfa
DrugBank: Onfekafusp alfa (DB16269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
Study: NCT02602600
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.~* Weight maintenance diet for 2 weeks
Study: NCT00642278
Drug: Canagliflozin (JNJ-28431754)
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
Study: NCT00642278
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
Study: NCT01858662
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
Study: NCT01858662
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
Study: NCT01858662
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
Study: NCT02013765
Drug: trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
Study: NCT00569920
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
Study: NCT00000451
Drug: sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 week outpatient study
Study: NCT00000451
Drug: naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 week outpatient study
Study: NCT03679481
Drug: Tranexamic acid (TXA)
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
Study: NCT00537940
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
Study: NCT00537940
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
Study: NCT02772497
Drug: Ziv aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
Study: NCT00199511
Drug: Administration of Hypertonic Solution 7.5% vs Mannitol 20%
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00653796
Drug: Ezetimibe + Atorvastatin
Normalized name: atorvastatin / ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
Study: NCT00653796
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
Study: NCT03993353
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg intravenously every 3 weeks
Study: NCT03993353
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg by mouth daily
Study: NCT00135434
Drug: Atazanavir/Ritonavir/Lopinavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03531229
Drug: Lu AF76432
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
Study: NCT00093119
Drug: ABI-007
Normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01094340
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fixed dose over 8 clinic visits
Study: NCT00634543
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
Study: NCT00685178
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial
Study: NCT01479088
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value \<180 pg/mL as tolerated by the patient
Study: NCT00084682
Drug: romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00731445
Drug: Z-208
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
Study: NCT00077623
Drug: epoetin alfa or beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: iv 3 times weekly, as prescribed
Study: NCT00077623
Drug: methoxy polyethylene glycol-epoetin beta (Mircera)
Normalized name: methoxy polyethylene glycol-epoetin beta Prefilled Syringe [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60, 100 or 180 micrograms sc (starting dose) every 2 weeks
Study: NCT00077623
Drug: methoxy polyethylene glycol-epoetin beta (Mircera)
Normalized name: methoxy polyethylene glycol-epoetin beta Prefilled Syringe [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60, 100 or 180 micrograms sc (starting dose) every 4 weeks
Study: NCT03378401
Drug: Octenidinedihydrochlorid
DrugBank: Octenidine (DB12624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
Study: NCT04524975
Drug: CD-008-0045
Normalized name: CD
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CD-008-0045 20 mg capsules
Study: NCT04220866
Drug: Ulevostinag
Normalized name: Ulevostinag
DrugBank: Ulevostinag (DB18789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT injection
Study: NCT02412644
Drug: apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00427388
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
Study: NCT00844298
Drug: Nilotinib+mVPD
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Induction:~   * Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)~  * Vincristine 2 mg iv push (d1, 8, 15, 22)~  * Prednisolone 60 mg/m2/day po (d1-28)~  * Nilotinib 400mg bid/d (d8-)~2. Consolidation A (cycle1)~   * Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)~  * Vincristine 2 mg iv (d1, 8)~  * Prednisolone 60 mg/m2/day po (d1-14)~  * Nilotinib 400mg bid/d~3. Consolidation B (cycles 2\&4)~   * Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)~  * Etoposide 150 mg/m2/day iv over 3 hours (d1-4)~  * Nilotinib 400mg bid/d~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)~  * Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,~  * Nilotinib 400mg bid/d~5. Maintenance~   ◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)~6. Consider alloHCT
Study: NCT03341104
Drug: Bupivacaine liposome
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Replace bupivacaine with bupivacaine liposome
Study: NCT03984760
Drug: Ferric Citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Take the capsules with meals or immediately after meals.
Study: NCT03984760
Drug: Sevelamer Carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take the tablets with meals.
Study: NCT00401973
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-20 milligrams (mg), oral, daily for 22 weeks.
Study: NCT00401973
Drug: amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
Study: NCT00401973
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
Study: NCT00401973
Drug: zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide, 100-400mg, oral, daily.
Study: NCT01264133
Drug: Clevudine, Adefovir
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd
Study: NCT02977897
Drug: Octreotide Acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide 100mcg SC q12h for 5 days
Study: NCT03515538
Drug: RRx-001
Normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRx-001 for injection
Study: NCT03515538
Drug: Cisplatin for injection
Normalized name: Cisplatin for Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
Study: NCT04075604
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified Dose on Specified Days
Study: NCT04075604
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified Dose on Specified Days
Study: NCT00538603
Drug: Paclitaxel & Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT03962049
Drug: Linzagolix
Normalized name: linzagolix
DrugBank: Linzagolix (DB17083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
Study: NCT02760602
Drug: Solanezumab
Normalized name: Solanezumab
DrugBank: Solanezumab (DB11756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00077181
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00077181
Drug: triapine
Normalized name: Triapine
DrugBank: Triapine (DB11940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02360371
Drug: Within-subject test of blinded study medication
Normalized name: salicylic acid Medicated Patch [Compound W brand of salicylic acid]
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within-subject double-blind, randomized, placebo-controlled, residential human abuse potential study. All participants received 4mg oral hydromorphone on study day 2 and a subset continued into the randomized portion for study days 3-5 wherein they received placebo, 2mg hydromorphone, and 8mg hydromorphone in randomized order. Only one dose was administered per day and following randomized all participants received each dose in random order. Outcomes were collected during 8-hour residential-based sessions and included metrics of FDA human abuse potential testing as well as secondary outcomes of laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition. Participants were genotyped for rs-1799971 status and results were analyzed as between-group comparisons based upon genotype.
Study: NCT03522298
Drug: Paxalisib (GDC-0084)
Normalized name: calcium carbonate
DrugBank: Paxalisib (DB15186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.
Study: NCT00784069
Drug: Lactic Acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic Acid (Dermacyd Breeze)
Study: NCT00320671
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.
Study: NCT00320671
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.
Study: NCT01858883
Drug: itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01858883
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01858883
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01858883
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03976856
Drug: GB226
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Geptanolimab, 210mg，q2w，ivgtt.
Study: NCT03976856
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib, 3mg or 4mg or 5mg, qd.po. 3 weeks-on,1 week-off
Study: NCT00045838
Drug: VCR-HIVDNA006-00-VP
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01802450
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00950352
Drug: Citicoline
Normalized name: Citicoline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
Study: NCT03839433
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01454089
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Study: NCT01454089
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Study: NCT01454089
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Study: NCT01382589
Drug: Afamelanotide
Normalized name: Afamelanotide
DrugBank: Afamelanotide (DB04931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
Study: NCT00471380
Drug: travoprost 0.004% and brinzolamide 1%
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)
Study: NCT00707954
Drug: TA-7284
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
Study: NCT03264638
Drug: Diane-35
Normalized name: Dianeal PD-2/2.5
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
Study: NCT02349906
Drug: Treosulfan
Normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT02349906
Drug: Busilvex
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes